Hector Naranjo Lopez
Family Medicine · Miami, FLNPI 1730323270
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Reporting peaked in 2020 at $930 and has fallen 96.1% since, to $37 in 2025.
Across 104 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$451
- AbbVie$221
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$208
- Pfizer$206
- AstraZeneca$167
- Kowa Pharmaceuticals America, Inc.$144
- plus $416 from 11 others
Across 48 payments — averaging $19,782 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$836K
- Teva Pharmaceuticals USA, Inc.$57K
- Gilead$56K
What the payments were for
- Food & beverage$1,813100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $451 |
| AbbVie(2 entities) | 21 | $221 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $208 |
| Pfizer | 12 | $206 |
| AstraZeneca | 11 | $167 |
| Kowa Pharmaceuticals America, Inc. | 9 | $144 |
| Amgen | 4 | $62 |
| GSK | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Intuitive Surgical | 1 | $52 |
| Novartis | 3 | $44 |
| Johnson & Johnson | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Mission Pharmacal Company | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$226
How this compares
$1,813 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 550 | $298,370 |
| TradjentaLinagliptin | 365 | $182,821 |
| JardianceEmpagliflozin | 309 | $179,686 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 580 | $61,735 |
| EntrestoSacubitril/Valsartan | 87 | $57,841 |
| EliquisApixaban | 71 | $40,171 |
| Insulin Aspart FlexpenInsulin Aspart | 297 | $38,216 |
| Tadalafil | 161 | $36,883 |
| FarxigaDapagliflozin Propanediol | 56 | $31,353 |
| TrulicityDulaglutide | 29 | $27,147 |
| Nifedipine ErNifedipine | 385 | $22,016 |
| Lubiprostone | 89 | $21,892 |
| LantusInsulin Glargine,hum.Rec.Anlog | 159 | $17,601 |
| Unifine PentipsPen Needle, Diabetic | 568 | $15,013 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $14,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $39 | $298,370550 claims |
| NovartisEntresto | $44 | $57,84187 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $167 | $54,03793 claims |
| PfizerEliquis | $206 | $40,17171 claims |
| GSKTrelegy Ellipta | $58 | $6,87111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.